Literature DB >> 2471199

Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

M Matsukura1, G Zon, K Shinozuka, M Robert-Guroff, T Shimada, C A Stein, H Mitsuya, F Wong-Staal, J S Cohen, S Broder.   

Abstract

In this report, we demonstrate the sequence-specific suppression of viral expression in T cells chronically infected with human immunodeficiency virus 1 (HIV-1), using antisense phosphorothioate oligodeoxynucleotides. As a target for antisense intervention, we used the HIV-1 gene rev, which is essential for viral replication and regulates the expression of virion proteins, in part, by affecting the splicing of the viral mRNA. A phosphorothioate oligomer complementary to the initiation sequence of HIV-1 rev had a significant and selective inhibitory effect on the production of several viral proteins in chronically HIV-1-infected T cells and drastically reduced the unspliced (genomic) viral mRNA transcripts, with relative sparing of smaller (spliced) transcripts. By contrast, the antisense sequence with unmodified normal phosphodiester linkages as well as phosphorothioate oligomers containing sense, random, homopolymeric sequences, or antisense sequence with N3-methylthymidine residues did not have an inhibitory effect on viral expression. Thus, sequence specificity and nuclease resistance were critical for the anti-viral-gene regulatory effect of the antisense molecules. The altered HIV-1 mRNA profile induced by the antisense phosphorothioate oligomer suggests that the mechanism for the inhibition of viral expression is due to an interference with the regulatory gene, rev, by translation arrest.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471199      PMCID: PMC287427          DOI: 10.1073/pnas.86.11.4244

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  The effect of substituents on the hydrogen bonding of adenine and uracil derivatives.

Authors:  Y Kyogoku; R C Lord; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1967-02       Impact factor: 11.205

2.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

3.  Post-transcriptional regulation accounts for the trans-activation of the human T-lymphotropic virus type III.

Authors:  C A Rosen; J G Sodroski; W C Goh; A I Dayton; J Lippke; W A Haseltine
Journal:  Nature       Date:  1986 Feb 13-19       Impact factor: 49.962

4.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

5.  Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides.

Authors:  J Goodchild; S Agrawal; M P Civeira; P S Sarin; D Sun; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

7.  Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro.

Authors:  S Hayashi; S Phadtare; J Zemlicka; M Matsukura; H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus.

Authors:  S Agrawal; J Goodchild; M P Civeira; A H Thornton; P S Sarin; P C Zamecnik
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus.

Authors:  M Matsukura; K Shinozuka; G Zon; H Mitsuya; M Reitz; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

10.  Oligodeoxynucleotide stability in subcellular extracts and culture media.

Authors:  E Wickstrom
Journal:  J Biochem Biophys Methods       Date:  1986-09
View more
  64 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 2.  Genetic engineering of plants for virus resistance.

Authors:  F Gadani; L M Mansky; R Medici; W A Miller; J H Hill
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Inhibition of gene expression by a short sense fragment.

Authors:  F H Cameron; P A Jennings
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

4.  Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups.

Authors:  C MacKellar; D Graham; D W Will; S Burgess; T Brown
Journal:  Nucleic Acids Res       Date:  1992-07-11       Impact factor: 16.971

5.  Inhibition of human immunodeficiency virus type 1 Rev-Rev-response element complex formation by complementary oligonucleotides.

Authors:  D J Chin
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates).

Authors:  W J Stec; A Grajkowski; M Koziolkiewicz; B Uznanski
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

7.  Modified deoxyoligonucleotides stable to exonuclease degradation in serum.

Authors:  J P Shaw; K Kent; J Bird; J Fishback; B Froehler
Journal:  Nucleic Acids Res       Date:  1991-02-25       Impact factor: 16.971

Review 8.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

9.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

10.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.